SAN RAMON, CA — CooperVision has acquired EnsEyes, a supplier of orthokeratology (ortho-k) and scleral contact lenses in the Nordic region. The company will operate within the CooperVision Specialty EyeCare group.
Financial terms of the deal were not disclosed.
Headquartered in Kolding, Denmark, EnsEyes has partnered with customers in Denmark, Sweden, Norway and Finland for the past decade, providing customized lenses and professional education. The acquisition is expected to help accelerate growth of specialty lens adoption across these markets, according to a press release.
“We have collaborated with EnsEyes for years, including its use of MyProcornea for lens ordering. Joining CooperVision will give its highly respected team more resources for growth, further build the expertise of our organization, and support eye care professionals’ soaring enthusiasm for specialty fitting,” said Juan Carlos Aragón, OD, president of CooperVision Specialty EyeCare.
More from the release:
CooperVision Specialty EyeCare develops, manufactures, and provides access to a portfolio of industry-leading soft and custom rigid gas permeable lens designs, including orthokeratology and scleral lenses to address segments such as myopia management, irregular cornea, and presbyopia. The group’s brands include Blanchard, GP Specialists, No7 Contact Lenses, Paragon, Procornea, and Soflex.
EnsEyes founder — optometrist and former CooperVision executive Esben Nørregaard Sørensen — will remain with the company. Customers should continue to work with their current EnsEyes representatives. Terms of the transaction were not disclosed.
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (“Cooper“) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Advertisement